Hercules Capital, Inc. $HTGC Shares Purchased by Prevail Innovative Wealth Advisors LLC

Prevail Innovative Wealth Advisors LLC increased its holdings in shares of Hercules Capital, Inc. (NYSE:HTGC) by 123.6% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 239,614 shares of the financial services provider’s stock after acquiring an additional 132,466 shares during the period. Prevail Innovative Wealth Advisors LLC’s holdings in Hercules Capital were worth $4,510,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the business. Leonteq Securities AG acquired a new stake in shares of Hercules Capital during the 4th quarter valued at about $141,000. Intrua Financial LLC acquired a new stake in shares of Hercules Capital during the 4th quarter valued at about $192,000. Everstar Asset Management LLC acquired a new stake in shares of Hercules Capital during the 4th quarter valued at about $218,000. Left Brain Wealth Management LLC lifted its stake in Hercules Capital by 1.7% in the 4th quarter. Left Brain Wealth Management LLC now owns 295,753 shares of the financial services provider’s stock valued at $5,566,000 after buying an additional 4,870 shares in the last quarter. Finally, GRIMES & Co WEALTH MANAGEMENT LLC purchased a new position in Hercules Capital in the 4th quarter valued at about $195,000. 19.69% of the stock is currently owned by institutional investors and hedge funds.

Hercules Capital Trading Up 2.1%

Shares of Hercules Capital stock opened at $15.64 on Thursday. The firm has a market capitalization of $2.93 billion, a PE ratio of 8.83 and a beta of 0.82. Hercules Capital, Inc. has a twelve month low of $13.70 and a twelve month high of $19.67. The firm’s 50-day moving average price is $15.16 and its 200 day moving average price is $16.77. The company has a current ratio of 1.89, a quick ratio of 1.89 and a debt-to-equity ratio of 1.14.

Hercules Capital (NYSE:HTGC) last released its earnings results on Tuesday, May 5th. The financial services provider reported $0.48 earnings per share for the quarter, topping analysts’ consensus estimates of $0.47 by $0.01. Hercules Capital had a net margin of 59.85% and a return on equity of 16.05%. The business had revenue of $134.94 million for the quarter, compared to analyst estimates of $141.39 million. During the same period last year, the company posted $0.45 EPS. The business’s revenue was up 18.4% on a year-over-year basis. On average, sell-side analysts predict that Hercules Capital, Inc. will post 1.93 EPS for the current fiscal year.

Hercules Capital Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 21st. Shareholders of record on Thursday, May 14th will be paid a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date of this dividend is Thursday, May 14th. Hercules Capital’s dividend payout ratio (DPR) is 90.40%.

Insiders Place Their Bets

In other Hercules Capital news, Director Robert P. Badavas bought 5,000 shares of the firm’s stock in a transaction on Friday, February 27th. The shares were acquired at an average cost of $14.27 per share, with a total value of $71,350.00. Following the purchase, the director directly owned 122,073 shares of the company’s stock, valued at $1,741,981.71. This trade represents a 4.27% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Thomas J. Fallon bought 20,000 shares of the firm’s stock in a transaction on Friday, February 27th. The stock was acquired at an average cost of $14.20 per share, for a total transaction of $284,000.00. Following the completion of the purchase, the director directly owned 150,369 shares in the company, valued at approximately $2,135,239.80. This represents a 15.34% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders bought 90,850 shares of company stock worth $1,333,812. 1.80% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on HTGC. Citizens Jmp decreased their price target on shares of Hercules Capital from $24.00 to $22.00 and set a “market outperform” rating on the stock in a research note on Wednesday, April 22nd. Weiss Ratings lowered shares of Hercules Capital from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, February 24th. Keefe, Bruyette & Woods decreased their price target on shares of Hercules Capital from $19.00 to $18.00 and set an “outperform” rating on the stock in a research note on Thursday, April 16th. Wells Fargo & Company decreased their price target on shares of Hercules Capital from $18.00 to $17.00 and set an “overweight” rating on the stock in a research note on Friday, February 13th. Finally, Piper Sandler raised their price target on shares of Hercules Capital from $16.50 to $17.00 and gave the company a “neutral” rating in a research note on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $18.21.

Hercules Capital Profile

Hercules Capital, Inc is a specialty finance company organized as a business development company (BDC) that provides tailored debt financing solutions to high‐growth companies. Through its external management structure, Hercules Capital extends senior secured loans, subordinated debt and growth capital designed to support research and development, expansion initiatives and working capital needs. The firm primarily partners with venture capital and private equity sponsors to finance innovative enterprises across various developmental stages.

The company’s investment portfolio is concentrated in technology, life sciences and sustainable and renewable technology sectors, reflecting its focus on industries with strong growth prospects and recurring capital requirements.